Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2021
Bristol Myers Squibb announces new PDUFA date for mavacamten
19 November 2021 - Bristol Myers Squibb today announced that the U.S. FDA has extended the review of the new ...
Posted by Michael Wonder on 22 Nov 2021
CRISPR Therapeutics announces FDA regenerative medicine advanced therapy designation granted to CTX110 for the treatment of relapsed or refractory CD19+ B-cell malignancies
22 November 2021 - CRISPR Therapeutics today announced that the U.S. FDA granted regenerative medicine advanced therapy designation to CTX110, ...
Posted by Michael Wonder on 22 Nov 2021
Pear Therapeutics receives FDA breakthrough device designation for prescription digital therapeutic candidate to treat alcohol use disorder
22 November 2021 – Pear Therapeutics today announced that it has received breakthrough device designation from the U.S. FDA for ...
Posted by Michael Wonder on 22 Nov 2021
bluebird bio Announces FDA priority review of biologics license application for beti-cel gene therapy for patients with β-thalassemia who require regular red blood cell transfusions
22 November 2021 - FDA set PDUFA date of 20 May 2022. ...
Posted by Michael Wonder on 22 Nov 2021
EMA evaluating data on booster dose of COVID-19 Vaccine Janssen
22 November 2021 - EMA has started evaluating an application for the use of a booster dose of COVID-19 Vaccine ...
Posted by Michael Wonder on 22 Nov 2021
FDA grants breakthrough designation for early stage breast cancer detection blood test developed by Datar Cancer Genetics
19 November 2021 - TriNetra is a circulating tumour cell detection blood test which is able to identify early stage ...
Posted by Michael Wonder on 22 Nov 2021
Obseva announces U.S. FDA acceptance of new drug application for linzagolix
22 November 2021 - FDA accepts new drug application for linzagolix for the management of heavy menstrual bleeding associated with uterine ...
Posted by Michael Wonder on 22 Nov 2021
TGA grants provisional determination to Grand Pacific for its COVID-19 protein-based subunit vaccine
22 November 2021 - The Therapeutic Goods Administration has granted provisional determination to Grand Pacific CRO (the Australian sponsor acting ...
Posted by Michael Wonder on 21 Nov 2021
Moderna files for authorisation of its COVID-19 vaccine with Health Canada to include children ages 6-11 years
17 November 2021 - Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11. ...
Posted by Michael Wonder on 20 Nov 2021
FDA grants Theradaptive breakthrough medical device designation
19 November 2021 - Theradaptive announced that the U.S. FDA has granted breakthrough medical device designation to its Osteo-Adapt SP Spinal ...
Posted by Michael Wonder on 20 Nov 2021
BioNTech receives FDA fast track designation for its FixVac candidate BNT111 in advanced melanoma
19 November 2021 - BioNTech today announced that the U.S. FDA granted fast track designation for BNT111, an investigational cancer ...
Posted by Michael Wonder on 20 Nov 2021
Pfizer's Xeljanz (tofacitinib) receives marketing authorisation in the European Union for the treatment of active ankylosing spondylitis
18 November 2021 - Pfizer announced today that the European Commission has approved Xeljanz (tofacitinib) 5 mg twice daily for the ...
Posted by Michael Wonder on 20 Nov 2021
Moderna announces FDA authorisation of booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older
19 November 2021 - Authorisation includes the use of Moderna’s booster dose following primary vaccination with other authorised or approved ...
Posted by Michael Wonder on 20 Nov 2021
EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19
19 November 2021 - EMA’s CHMP has issued advice on the use of Lagevrio (molnupiravir, MK 4482) for the treatment of ...
Posted by Michael Wonder on 20 Nov 2021
EMA starts review of Paxlovid for treating patients with COVID-19
19 November 2021 - EMA is reviewing currently available data on the use of Paxlovid (PF-07321332/ritonavir), an oral treatment for COVID-19 ...